Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia.

AuthorsDowman, LM
McDonald, CF
Bozinovski , S
Gillies, R
Pouniotis, D
Hill, CJ
Goh, NS
Holland, AE
TypeJournal Article (Original Research)
PubMed ID28225205
Year of Publication2017
Download Dowman_et_al-2017-Respirology.pdf (1.2 MB)
AbstractBACKGROUND AND OBJECTIVE: Supplemental oxygen is commonly prescribed in patients with idiopathic pulmonary fibrosis (IPF), although its benefits have not been proven. The aims of this study were to investigate the effect of oxygen on oxidative stress, cytokine production, skeletal muscle metabolism and physiological response to exercise in IPF. METHODS: Eleven participants with IPF received either oxygen, at an FiO2 of 0.50, or compressed air for 1 h at rest and during a cycle endurance test at 85% of peak work rate. Blood samples collected at rest and during exercise were analysed for markers of oxidative stress, skeletal muscle metabolism and cytokines. The protocol was repeated a week later with the alternate intervention. RESULTS: Compared with air, oxygen did not adversely affect biomarker concentrations at rest and significantly improved endurance time (mean difference = 99 +/- 81s, P = 0.002), dyspnoea (-1 +/- 1 U, P = 0.02), systolic blood pressure (BP; -11 +/- 11 mm Hg, P = 0.006), nadir oxyhaemoglobin saturation (SpO2 ; 8 +/- 6%, P = 0.001), SpO2 at 2-min (7 +/- 6%, P = 0.003) and 5-min isotimes (5 +/- 3, P < 0.001) and peak exercise xanthine concentrations (-42 +/- 73 micromol/L, P = 0.03). Air significantly increased IL-10 (5 +/- 5 pg/mL, P = 0.04) at 2-min isotime. Thiobarbituric acid-reactive substances (TBARs), IL-6, TNF-alpha, creatine kinase, lactate, heart rate and fatigue did not differ between the two interventions at any time point. CONCLUSION: In patients with IPF, breathing oxygen at FiO2 of 0.50 at rest seems safe. During exercise, oxygen improves exercise tolerance, alleviates exercise-induced hypoxaemia and reduces dyspnoea. A potential relationship between oxygen administration and improved skeletal muscle metabolism should be explored in future studies.

< More publications


Each year in Australia 260 people sustain a SCI, with over half losing full function in their arms and legs (quadriplegia). In addition to the primary disability, there is a very high rate of Obstructive...

Notch monitoring in sleepNOTCH MONITORING IN SLEEP

Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...

NTC releases 'world first' heavy vehicle driver fatigue studyNTC RELEASES 'WORLD FIRST' HEAVY VEHICLE DRIVER FATIGUE STUDY

The National Transport Commission (NTC) and the Cooperative Research Centre for Alertness, Safety and Productivity (Alertness CRC) have released the results of what is hailed as a world-first study into heavy vehicle driver fatigue.

AAMRI Election Statement released on 25th March 2019AAMRI ELECTION STATEMENT RELEASED ON 25TH MARCH 2019

AAMRI released its election statement calling on politicians to commit to three main priorities: ensuring the MRFF reaches $20 billion by 2020-21, provide continued strong support for the NHMRC, and develop sustainable and rewarding career pathways.

IBAS Director Anna Burke unveils her portrait at Canberra's Parliament HouseIBAS DIRECTOR ANNA BURKE UNVEILS HER PORTRAIT AT CANBERRA'S PARLIAMENT HOUSE

Anna Burke had barely got into the swing of her speech at the unveiling of her portrait at Canberra's Parliament House when the ringing of bells caused half her audience to hurry away

National study offers hope for breathlessnessNATIONAL STUDY OFFERS HOPE FOR BREATHLESSNESS

A national medication study is aiming to help thousands of Australians who struggle every day with shortness of breath

Institute for Breathing and Sleep

Level 5, Harold Stokes Building, Austin Hospital
145 Studley Road
Heidelberg, Victoria, 3084

(03) 9496 5390

Email Us